|
|
News Breaks | | | | September 10, 2012 | | 07:08 EDT |  | PPHM | Peregrine Pharma price target raised to $6.50 from $5 at JMP Securities
JMP Securities increased its target on Peregrine after the company announced results of the trial of its bavituximab for second-line, non-small cell lung cancer patients that demonstrated an overall survival benefit which was approximately double the duration observed in the control arm. The firm thinks the results could bode well for the company's Phase III program and partnership talks, and it reiterates an Outperform rating on the shares. | |
|
News For PPHM From The Last 14 Days Check below for free stories on PPHM the last two weeks. |
|
|
| June 10, 2013 | | 12:28 EDT |  | PPHM | Peregrine management to meet with Roth Capital
 Subscribe for More Information | |
|
|
|
|
|
|
